The mechanisms through which LH-RH antagonists suppress gonadotroph functions and LH-RH receptor (LH-RH-R) production are incompletely understood. To elucidate these mechanisms, we investigated the effects of Cetrorelix on the mRNA expression of pituitary LH-RH-R and luteinizing hormone (LH) secretion in three experimental systems with different pituitary LH-RH environments. Ovariectomy induced 3.61-fold and 6.34-fold increases in the mRNA expression of pituitary LH-RH-R in rats after 11 and 21 days, respectively. After (5 h) a single injection of 100 g Cetrorelix, no significant decrease occurred in the mRNA levels of pituitary LH-RH-R in ovariectomized (OVX) rats with high pituitary exposure to LH-RH, but there was a significant 23.2% reduction in cycling rats with normal hypophysial LH-RH environment. Prolonged treatment for 10 days with a Cetrorelix depot formulation releasing 100 g͞day decreased the concentration of mRNA for pituitary LH-RH-R by 72.6% in OVX rats, but only by 32.9% in normal rats. The decline in serum LH was 98.7% in OVX rats and 63.2% in normal rats, resulting in a minimal 0.1-0.2 ng͞ml LH concentration in both groups. A continuous exposure of pituitary cells to 100 nM Cetrorelix in the superfusion system, which is devoid of LH-RH, did not cause any significant changes in LH-RH-R mRNA level. These studies demonstrate that prolonged exposure to Cetrorelix in vivo, but not in vitro, down-regulates the mRNA expression of the pituitary receptors for LH-RH. Our findings indicate that LH-RH antagonists exert their inhibitory effects on the gene expression of pituitary LH-RH-R by counteracting the stimulatory effect of endogenous LH-RH.T he hypothalamic decapeptide LH-RH plays a pivotal role in regulating luteinizing hormone (LH) and follicle-stimulating hormone secretion through the activation of high-affinity G protein-coupled receptors on the plasma membrane of pituitary gonadotrophs (1-3). The responsiveness of the gonadotrophs to LH-RH varies under different conditions, depending on the hormonal milieu (4, 5), and seems to be correlated at least in part with the number of LH-RH receptors (6, 7). The regulation of the number and the responsiveness of LH-RH-Rs is complex, being influenced by gonadal steroids, inhibin, and gonadotropins, as well as by its own ligand, LH-RH (5, 8-10). An intermittent administration of native LH-RH or LH-RH agonists in vivo and in vitro, mimicking the natural pulsatile release of this neuropeptide from the hypothalamus, stimulates the synthesis and the release of gonadotropins and leads to an increase in the number of its receptors (11). However, continuous administration of LH-RH and its agonists, especially at high concentration, causes a downregulation of receptors and desensitization of gonadotrophs (11-13). Thus, administration of depot preparations of LH-RH agonists results in the suppression of the secretion of gonadotropins and sex hormones which provides the basis for clinical applications of this class of compounds (1, 2, 14).In the past 25 years, more ...